Pancreatic Cancer Research

ResearcherTongji UniversityActive in the last 2 years

Bo Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9099-6248; OpenAlex author ID A5100427385. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2021: 3 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers

Papers 9

  1. Neurturin-induced activation of GFRA2-RET axis potentiates pancreatic cancer glycolysis via phosphorylated hexokinase 2. Last author DOI 10.1016/j.canlet.2025.217583↗
  2. Prognostic and immunotherapeutic potential of disulfidptosis-associated signature in pancreatic cancer. Co-author DOI 10.3389/fimmu.2025.1568976↗
  3. Comprehensive analysis based on the disulfidptosis-related genes identifies hub genes and immune infiltration for pancreatic adenocarcinoma. Co-author DOI 10.1515/med-2024-0906↗
  4. The gene RAD51AP1 promotes the progression of pancreatic cancer via the PI3K/Akt/NF-κB signaling pathway. Co-author DOI 10.4149/neo_2023_230614n310↗
  5. Identification of LIPH as an unfavorable biomarkers correlated with immune suppression or evasion in pancreatic cancer based on RNA-seq. Co-author DOI 10.1007/s00262-021-03019-x↗
  6. A high bile acid environment promotes apoptosis and inhibits migration in pancreatic cancer. Last author DOI 10.1080/21655979.2022.2045823↗
  7. Exploring the significance of novel immune-related gene signatures in the prognosis and immune features of pancreatic adenocarcinoma. Co-author DOI 10.1016/j.intimp.2020.107359↗
  8. Prognostic values and immune suppression of the S100A family in pancreatic cancer. Co-author DOI 10.1111/jcmm.16343↗
  9. Prognostic Nomogram for Patients With Pancreatic Ductal Adenocarcinoma of Pancreatic Head After Pancreaticoduodenectomy. Co-author DOI 10.1177/11795549211024149↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ran Cui · 3 shared papers, 2023–2025 · strength 0.70
  2. Yongkun Wang · 3 shared papers, 2023–2025 · strength 0.70
  3. Chuanzhao Zhang · 3 shared papers, 2021–2022 · strength 0.44
  4. Hongkai Zhuang · 3 shared papers, 2021–2022 · strength 0.44
  5. Shanzhou Huang · 3 shared papers, 2021–2022 · strength 0.44
  6. Xiaohua Jiang · 1 shared paper, 2025 · strength 0.27
  7. Yu Li · 1 shared paper, 2024 · strength 0.26
  8. Zefeng Xie · 1 shared paper, 2024 · strength 0.26
  9. Zuyi Ma · 2 shared papers, 2021 · strength 0.25
  10. Zixuan Zhou · 2 shared papers, 2021 · strength 0.25
  11. Baohua Hou · 2 shared papers, 2021 · strength 0.25
  12. Xiaohua Jiang · 1 shared paper, 2025 · strength 0.24
  13. Xiaohua Jiang · 1 shared paper, 2023 · strength 0.19
  14. Shaopu Zhu · 1 shared paper, 2022 · strength 0.17
  15. Maoming Xiong · 1 shared paper, 2022 · strength 0.17
  16. Li Zhang · 1 shared paper, 2022 · strength 0.17
  17. Chuan Liu · 1 shared paper, 2021 · strength 0.15
  18. Yuanfeng Gong · 1 shared paper, 2021 · strength 0.12
  19. Shujie Wang · 1 shared paper, 2021 · strength 0.12
  20. Zhenchong Li · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.